Tobacco smoke affects expression of peroxisome proliferator‐activated receptor‐γ in monocyte/macrophages of patients with coronary heart disease
Open Access
- 20 October 2009
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (5) , 1276-1284
Abstract
Background and purpose: Tobacco smoke represents a relevant risk factor for coronary heart disease (CHD). Although peroxisome proliferator‐activated receptor (PPAR)γ activation reduces inflammation and atherosclerosis, expression of PPARγ in cells and its modulation by smoking are poorly investigated. We previously reported that monocyte/macrophages from healthy smokers exhibited an enhanced constitutive expression of PPARγ. Here, we evaluated PPARγ expression and basal cytokine release in monocytes and monocyte‐derived macrophages (MDMs) from 85 CHD patients, classified by their smoking habit (smokers, non‐smokers and ex‐smokers), and assessed the role of PPARγ ligands in this context.Experimental approach: PPARγ protein was detected by Western blot and semi‐quantified by PPARγ/β‐actin ratio; cytokine release was measured byelisaand nuclear factor‐kappaB (NF‐κB) translocation by electrophoretic mobility shift assays.Key results: As compared to the other groups, MDMs from smoker CHD patients exhibited a reduced PPARγ/β‐actin ratio and an increased spontaneous release of tumour necrosis factor‐α (TNF‐α) and interleukin‐6, but with no major variations in monocytes. In cells from selected CHD patients, rosiglitazone inhibited TNF‐α release and NF‐κB translocation induced by phorbol‐12‐myristate 13‐acetate. The selective PPARγ antagonist GW9662 reversed these effects, with some variations related to smoking habit.Conclusions and implications: In CHD patients, exposure to tobacco smoke profoundly affected PPARγ expression, and this was related to levels of secretion of pro‐inflammatory cytokines. MDMs from CHD smokers showed the lowest PPARγ expression and released more inflammatory cytokines. Moreover, rosiglitazone's ability to inhibit cytokine release and its reversal by GW9662 clearly indicated PPARγ involvement in these changes in CHD patients.Keywords
This publication has 27 references indexed in Scilit:
- A novel activity for substance P: stimulation of peroxisome proliferator‐activated receptor‐γ protein expression in human monocytes and macrophagesBritish Journal of Pharmacology, 2008
- Guide to Receptors and Channels (GRAC), 3rd editionBritish Journal of Pharmacology, 2008
- Rosiglitazone and 15-Deoxy-Δ 12,14 -Prostaglandin J 2 , PPAR γ Agonists, Differentially Regulate Cigarette Smoke-Mediated Pro-Inflammatory Cytokine Release in Monocytes/MacrophagesAntioxidants & Redox Signaling, 2008
- Nuclear receptors in macrophages: A link between metabolism and inflammationFEBS Letters, 2007
- Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cellsCytokine, 2007
- Quantification of PPAR-γ protein in monocyte/macrophages from healthy smokers and non-smokers: A possible direct effect of nicotineLife Sciences, 2007
- Peroxisome proliferator-activated receptor-γ inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cellsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Macrophage‐stimulating protein differently affects human alveolar macrophages from smoker and non‐smoker patients: evaluation of respiratory burst, cytokine release and NF‐κB pathwayBritish Journal of Pharmacology, 2006
- Expression of functional NK1 receptors in human alveolar macrophages: superoxide anion production, cytokine release and involvement of NF‐κB pathwayBritish Journal of Pharmacology, 2005
- Plasma tumour necrosis factor-α and early carotid atherosclerosis in healthy middle-aged menEuropean Heart Journal, 2002